Journal of Clinical and Experimental Ophthalmology
Open Access

Galveston Clinical Research Foundation, Galveston, USA

Publications

• Short Communication   
  Treatments for Dry Eye Disease: A Comparison Analysis
  Author(s): Buck F Willis*, Justus W Thomas, Mark C Vital and John D Goosey
  
  Dry eye Disease (DED) effects up to 30% of the global population (2.25 Billion people) and this inflammatory condition of ocular surfaces has symptoms of visual disturbances, eye discomfort, tear film instability, etc. In the United States the average cost of treating this anomaly is over $6,500 with incidence rate of up to 20 million patients. This meeting will discuss three primary treatments of Cyclosporine 5%, Lifitegrast, and studies showing significance and differences between these treatments. A recent Systematic Review with meta-analysis was conducted on studies of Topical Cyclosporine 5% (Restasis®; Allergan, Inc., Irvine, CA). The 12 studies (mean 25 weeks) included 629 subjects receiving treatment of Restasis. The outcome measure shared between these studies was the Schirmer #1 test and the mean score reduction was 2.7 mm. A retrospective case/control .. View More»
  DOI: 10.35248/2155-9570.21.11.857

  Abstract HTML PDF